Melanie E. Neary

Melanie Neary is a partner in the San Francisco office of Gibson Dunn where she practices in the firm’s Capital Markets Practice Group, focusing on representing leading life sciences companies and investors. Melanie advises clients on a wide range of complex financing transactions and matters, including initial public offerings, secondary equity offerings, and venture and growth equity financings, as well as mergers and acquisitions, spin-offs, and PIPEs. Melanie regularly serves as principal outside counsel for numerous publicly-traded companies and advises management and boards of directors on corporate law matters, Securities and Exchange Commission reporting requirements and ownership filings, and corporate governance.

Representative Clients and Transactions:

• Initial Public Offerings: Apogee Therapeutics, Rain Oncology, Shattuck Labs, Biora Therapeutics, 89bio, Cricut, StepStone Group, Petco Health and Wellness Company, Odonate Therapeutics, Excelerate Energy
• Follow-on Equity Offerings: Apogee Therapeutics, Spyre Therapeutics, Shattuck Labs, Biora Therapeutics, Protagonist Therapeutics, Ultragenyx Pharmaceutical, 89bio, Odonate Therapeutics, Rain Oncology, Rockwell Medical, Heron Therapeutics, Rocket Pharmaceuticals, StepStone Group, Leslie’s, Peloton, Eledon Pharmaceuticals, Viridian Therapeutics
• PIPE Offerings: Shattuck Labs, Viridian Therapeutics, Spyre Therapeutics, Dianthus Therapeutics, Biora Therapeutics
• ATM Facilities: Protagonist Therapeutics, Shattuck Labs, Rain Oncology, Biora Therapeutics, Ultragenyx, Viridian Therapeutics, 89bio, Rockwell Medical, California Water Service Group, Urovant
• Debt Offerings: Mauser Packaging, California Water Service Group, Wells Fargo & Company and Wells Fargo Bank, N.A., Gran Tierra Energy, Keysight Technologies, Magnite
• Venture Financings: Apogee Therapeutics – Series B, Cullgen – Series C, Perceive Biotherapeutics – Series B, Ellodi Pharmaceuticals – Series B, Tourmaline Bio – Series A, Jaanuu – Series B, Waterloo Sparkling Water – Series D, Bandier – Series E, ConnectRN – Series F, Sling Therapeutics – Series B
• Mergers and Acquisitions:
  • Cullgen in its business combination with Pulmatrix
  • Quidel in its acquisition of Ortho Clinical Diagnostics
  • Glassdoor in its sale to Recruit Holdings
  • BPGBio in its investment in Berg, LLC
  • California Water Service Group in proposed acquisition of SJW Group
  • Novus Therapeutics in its merger transaction with Tokai Pharmaceuticals
  • Rocket Pharmaceuticals in its merger transaction with Inotek